MedPath

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2
Terminated
Conditions
Mesothelioma
Interventions
Registration Number
NCT01907100
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
545
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo + pemetrexed/cisplatinPlaceboPlacebo controlled arm
Placebo + pemetrexed/cisplatinPemetrexedPlacebo controlled arm
Placebo + pemetrexed/cisplatinCisplatinPlacebo controlled arm
Nintedanib 200mg + pemetrexed/cisplatinNintedanibExperimental arm
Nintedanib 200mg + pemetrexed/cisplatinCisplatinExperimental arm
Nintedanib 200mg + pemetrexed/cisplatinPemetrexedExperimental arm
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS)From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)

This outcome measure presents progression-free survival. Disease progression was defined according to the modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Progression-free survival time was calculated as the duration from the date of randomization to the date of disease progression or death, whichever occurred first. For patients with known date of progression (or death): PFS (days) = min (date of progression, date of death) - date of randomization + 1 day. For patients without progression or death, PFS was censored at the last imaging date that showed no disease progression: PFS (days, censored) = date of last imaging showing no progression - date randomization + 1 day.

Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS)From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)

Overall survival was defined as the duration of time from randomization to time of death.

This is the key secondary endpoint of the trial.

Objective Response According to Modified RECIST- Investigator AssessmentTumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months

Objective response (best overall tumour response of confirmed complete response \[CR\] or confirmed partial response \[PR\]).

Complete Response: disappearance of all target lesions Partial Response: at least a 30 % decrease in the total tumour measurement of target lesions, taking as reference the baseline total tumour measurement.

Percentage of Patients with confirmed objective response is presented. This endpoint was only evaluated for Phase III part.

Disease Control According to Modified RECIST- Investigator AssessmentTumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months

Disease control (best overall response of confirmed CR or PR, or Stable Disease (SD) that lasted ≥36 days) according to modified RECIST.

Percentage of Patients with Disease control is presented. This endpoint was only evaluated for Phase III part.

Trial Locations

Locations (122)

Northern Cancer Institute

🇦🇺

St Leonards, New South Wales, Australia

Texas Oncology - McAllen

🇺🇸

McAllen, Texas, United States

Cancer Care Northwest Centers, PS

🇺🇸

Spokane Valley, Washington, United States

Mater Cancer Care Centre

🇦🇺

South Brisbane, Queensland, Australia

Clínica Universitaria Reina Fabiola

🇦🇷

Ciudad de Cordoba, Argentina

Instituto Medico Especializado Alexander Fleming

🇦🇷

Ciudad Autónoma de Bs As, Argentina

Texas Oncology-San Antonio Northeast

🇺🇸

San Antonio, Texas, United States

Calvary Mater Newcastle Hospital

🇦🇺

Waratah, New South Wales, Australia

Sir Charles Gairdner Hospital

🇦🇺

Nedlands, Western Australia, Australia

Perth Oncology

🇦🇺

Perth, Western Australia, Australia

Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi

🇹🇷

Istanbul, Turkey

Onco.Cent. - Instit. of Maria Sklodowskiej-Curie

🇵🇱

Warsaw, Poland

Nasser Institute

🇪🇬

Cairo, Egypt

AKH - Medical University of Vienna

🇦🇹

Vienna, Austria

Centro Oncologico Estatal ISSEMYM

🇲🇽

Toluca, Mexico

IUCPQ (Laval University)

🇨🇦

Quebec, Canada

Japan Labour Health and Safety Organization Okayama Rosai Hospital

🇯🇵

Okayama, Okayama, Japan

SBI HC-Rep.Clin.Onc.Disp.MoH.Rep.Bashkortostan

🇷🇺

Ufa, Russian Federation

University of California San Francisco

🇺🇸

San Francisco, California, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Greenville Health System

🇺🇸

Greenville, South Carolina, United States

The University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Sanatorio Güemes

🇦🇷

Ciudad Autónoma de Bs As, Argentina

Peninsula Haematology & Oncology

🇦🇺

Frankston, Victoria, Australia

The Prince Charles Hospital

🇦🇺

Chermside, Queensland, Australia

Austin Health

🇦🇺

Heidelberg, Victoria, Australia

Border Onclogy Research

🇦🇺

Wodonga, Victoria, Australia

LKH Leoben

🇦🇹

Leoben, Austria

Klinikum Wels - Grieskirchen GmbH

🇦🇹

Wels, Austria

Edegem - UNIV UZ Antwerpen

🇧🇪

Edegem, Belgium

Brussels - UNIV Saint-Luc

🇧🇪

Bruxelles, Belgium

UNIV UZ Gent

🇧🇪

Gent, Belgium

AZ Sint-Maarten

🇧🇪

Mechelen, Belgium

QEII Health Sciences Centre (Dalhousie University)

🇨🇦

Halifax, Nova Scotia, Canada

Health Sciences North

🇨🇦

Sudbury, Ontario, Canada

Princess Margaret Cancer Centre

🇨🇦

Toronto, Ontario, Canada

Centro Internacional de Estudios Clínicos - CIEC

🇨🇱

Recoleta, Chile

University Clinic for Pulmonary Diseases

🇭🇷

Zagreb, Croatia

Orlandi Oncologia

🇨🇱

Vitacura, Chile

University Hospital Brno

🇨🇿

Brno, Czechia

Rigshospitalet, København, Onkologisk afdeling

🇩🇰

Købenahvn Ø, Denmark

University Hospital Olomouc

🇨🇿

Olomouc, Czechia

Medical Research Institute

🇪🇬

Alexandria, Egypt

Clinical Research Center Alexandria

🇪🇬

Alexandria, Egypt

CLI Bordeaux Nord Aquitaine

🇫🇷

Bordeaux, France

HOP Côte de Nacre

🇫🇷

Caen, France

National Cancer Institute, Cairo University

🇪🇬

Cairo, Egypt

HOP Morvan

🇫🇷

Brest, France

HOP Lyon Sud

🇫🇷

Pierre-Bénite, France

HOP Calmette

🇫🇷

Lille, France

INS Gustave Roussy

🇫🇷

Villejuif, France

HOP Larrey

🇫🇷

Toulouse, France

HOP Nord

🇫🇷

Marseille, France

Helios Klinikum Emil von Behring

🇩🇪

Berlin, Germany

Klinik Schillerhöhe GmbH

🇩🇪

Gerlingen, Germany

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH

🇩🇪

Großhansdorf, Germany

Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

🇩🇪

Heidelberg, Germany

Sourasky Medical Center

🇮🇱

Tel-Aviv, Israel

Rabin Medical Center Beilinson

🇮🇱

Petach Tikva, Israel

Universitätsklinikum des Saarlandes

🇩🇪

Homburg/Saar, Germany

Klinik, Löwenstein

🇩🇪

Löwenstein, Germany

Istituto Nazionale per la Ricerca sul Cancro

🇮🇹

Genova, Italy

Humanitas Gavazzeni

🇮🇹

Bergamo, Italy

Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo

🇮🇹

Alessandria, Italy

Centro di riferimento Oncologico

🇮🇹

Aviano (PN), Italy

Azienda Sanitaria Ospedale S. Luigi Gonzaga

🇮🇹

Orbassano (TO), Italy

A.O.U. Senese Policlinico Santa Maria alle Scotte

🇮🇹

Siena, Italy

University Hospital of Occupational and Environmental Health

🇯🇵

Fukuoka, Kitakyushu, Japan

Hyogo Prefectural Amagasaki General Medical Center

🇯🇵

Hyogo, Amagasaki, Japan

Hyogo College of Medicine Hospital

🇯🇵

Hyogo, Nishinomiya, Japan

Yokosuka Kyosai Hospital

🇯🇵

Kanagawa , Yokosuka, Japan

Kindai University Hospital

🇯🇵

Osaka, OsakaSayama, Japan

Otemae Hospital

🇯🇵

Osaka, Osaka, Japan

Juntendo University Hospital

🇯🇵

Tokyo, Bunkyo-ku, Japan

Centro Oncologico de Chihuahua

🇲🇽

Chihuahua, Mexico

Instituto Nacional de Cancerologia

🇲🇽

Mexico, Mexico

Medisch Spectrum Twente

🇳🇱

Enschede, Netherlands

Oslo Universitetssykehus HF, Radiumhospitalet

🇳🇴

Oslo, Norway

St. Olavs Hospital, Universitetssykehuset i Trondheim

🇳🇴

Trondheim, Norway

Zuyderland Medisch Centrum

🇳🇱

Heerlen, Netherlands

Erasmus Medisch Centrum

🇳🇱

Rotterdam, Netherlands

University Clinical Center, Gdansk

🇵🇱

Gdansk, Poland

Greater PL Cent.Pulmo.&Thor.Surg.Eugenia&Janusz Zeyland

🇵🇱

Poznan, Poland

Clin.Hosp.Med.Univ.Marcinkowski in Poznan

🇵🇱

Poznan, Poland

Hospital CUF Porto

🇵🇹

Porto, Portugal

Centro Hospitalar Lisboa Norte Hospital Pulido Valente

🇵🇹

Lisboa, Portugal

St.Budg.Heal.Inst."Chelyabinsk Reg.Clin.Cen.Onc&Nucl.Med"

🇷🇺

Chelyabinsk, Russian Federation

St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"

🇷🇺

Kazan, Russian Federation

FSBI "N.N Blokhin Med.Res.Cent.Onc."MoH of RF

🇷🇺

Moscow, Russian Federation

Wilgers Oncology Centre

🇿🇦

Pretoria, South Africa

FSBI "N.N. Petrov National Medical Research Center of Oncology" of MoH of RF

🇷🇺

Saint-Petersburg, Russian Federation

1stPavlov St.Med.Univ.St.-Petersburg Res.Inst.

🇷🇺

Saint-Petersburg, Russian Federation

Hospital Universitario de Cruces

🇪🇸

Barakaldo (Vizcaya), Spain

Hospital Universitario Donostia

🇪🇸

Donostia (Gipuzkoa), Spain

Hospital Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital Clínic de Barcelona

🇪🇸

Barcelona, Spain

Hospital Virgen del Rocío

🇪🇸

Sevilla, Spain

Hospital Virgen de la Victoria

🇪🇸

Malaga, Spain

Hospital Duran i Reynals

🇪🇸

L'Hospitalet de Llobregat, Spain

Hospital Ramón y Cajal

🇪🇸

Madrid, Spain

Hospital Clínico de Valencia

🇪🇸

Valencia, Spain

Universitetssjukhuset, Linköping

🇸🇪

Linköping, Sweden

Karolinska Univ. sjukhuset

🇸🇪

Stockholm, Sweden

Skånes universitetssjukhus, Lund

🇸🇪

Lund, Sweden

Akademiska sjukhuset

🇸🇪

Uppsala, Sweden

Eskisehir Osmangazi Üni. Sag. Uygulama ve Arastirma Has.

🇹🇷

Eskisehir, Turkey

Dr.Suat Seren EAH

🇹🇷

Izmir, Turkey

Western General Hospital

🇬🇧

Edinburgh, United Kingdom

Beatson West of Scotland Cancer Centre

🇬🇧

Glasgow, United Kingdom

Leicester Royal Infirmary

🇬🇧

Leicester, United Kingdom

The Royal Marsden Hospital

🇬🇧

Sutton, United Kingdom

Sahlgrenska US, Göteborg

🇸🇪

Göteborg, Sweden

Wythenshawe Hospital

🇬🇧

Wythenshawe, United Kingdom

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Rocky Mountain Cancer Centers

🇺🇸

Littleton, Colorado, United States

Comprehensive Cancer Centers of Nevada

🇺🇸

Henderson, Nevada, United States

HOP HIA Saint-Anne

🇫🇷

Toulon, France

Box Hill Hospital

🇦🇺

Box Hill, Victoria, Australia

Rambam Medical Center

🇮🇱

Haifa, Israel

Vivantes Netzwerk für Gesundheit GmbH

🇩🇪

Berlin, Germany

UZ Leuven

🇧🇪

Leuven, Belgium

Guy's Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath